Hana Florian

812 citations

20 papers · 502 indexed · h-index 8

Co-authors: I. Jon Russell Philip J. Mease Susan Martin Lesley M. Arnold James P. Young Uma Sharma Ahmed A. Othman Nuno Mendonça
Topics: Alzheimer's disease research and treatments (7 papers)Health Systems, Economic Evaluations, Quality of Life (5 papers)Cholinesterase and Neurodegenerative Diseases (4 papers)
Cited by: Pharmacology Psychiatry and Mental health Biological Psychiatry
Journals: Brain Journal of Alzheimer s Disease British Journal of Clinical Pharmacology
Partner nations: United States Germany Egypt

In The Last Decade

Hana Florian

18 papers receiving 493 citations

Peers

Countries citing papers authored by Hana Florian

Since Specialization

Citations

This map shows the geographic impact of Hana Florian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hana Florian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hana Florian more than expected).

Fields of papers citing papers by Hana Florian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hana Florian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hana Florian. The network helps show where Hana Florian may publish in the future.

Co-authorship network of co-authors of Hana Florian

This figure shows the co-authorship network connecting the top 25 collaborators of Hana Florian. A scholar is included among the top collaborators of Hana Florian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hana Florian. Hana Florian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Using AI‐generated digital twins to boost clinical trial efficiency in Alzheimer's disease 2025 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Deli Wang,Hana Florian,(unknown),Weining Robieson,Run Zhuang,(unknown),Jessica L. Ross,John R. Walsh,Ole Graff	0
2	Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting 2025 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Ronald C. Petersen,Ana Graf,(unknown),Susan De Santi,Hana Florian,Jaren W. Landen,(unknown),Christopher Randolph,Kaycee M. Sink,Marı́a C. Carrillo,Christopher J. Weber	1
3	Assessment of AI‐generated digital twin (DT) methodology on reduction of treatment effect variance and potential clinical trial sample size saving using a Phase 2 trial dataset from patients with Alzheimer’s disease (AD) 2024 ·Alzheimer s & Dementia ·Deli Wang,Hana Florian,(unknown),Weining Robieson,Li Wang,Sheng Zhong,(unknown),Run Zhuang,(unknown),Stefanie J. Millar,M.F. Turner,J. A. Ross,Jonathan R. Walsh,(unknown),Ole Graff	1
4	Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study 2023 ·Brain ·Hana Florian,Deli Wang,Steven E. Arnold,Merçé Boada,Qi Guo,Ziyi Jin,Hui Zheng,Nahome Fisseha,Hari V. Kalluri,Beatrice Rendenbach‐Mueller,(unknown),Michael Gold	74
5	Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations 2023 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Ronald C. Petersen,Ana Graf,(unknown),Susan De Santi,Hana Florian,Jaren W. Landen,(unknown),Christopher Randolph,Kaycee M. Sink,María C. Carrillo,Christopher J. Weber	3
6	Apheleia‐001: A novel prescreening study designed to enrich and accelerate Alzheimer’s disease clinical trials by efficiently identifying trial‐eligible participants determined to have a high probability of study inclusion, including amyloid positivity 2023 ·Alzheimer s & Dementia ·(unknown),(unknown),(unknown),(unknown),(unknown),Amanda Ng,Christina M. Brown,(unknown),(unknown),(unknown),(unknown),Hana Florian,(unknown),(unknown),Anthony W. Bannon,(unknown),Julie Schwartzbard	0
7	A polygenic risk score (PRS) predicts cognitive decline in the APOE3 population in an early Alzheimer’s disease clinical trial cohort 2023 ·Alzheimer s & Dementia ·Aparna Vasanthakumar,Qian Gao,(unknown),(unknown),Alex Gibson,Hana Florian,Jeffrey F. Waring	1
8	Putting participants and study partners FIRST when clinical trials end early 2022 ·Alzheimer s & Dementia ·Emily A. Largent,Sarah Walter,Nancy M. Childs,(unknown),(unknown),Hana Florian,Jonathan Jackson,Jorge J. Llibre Guerra,Erin Iturriaga,David S. Miller,(unknown),Rachel L. Nosheny,Thomas O. Obisesan,Elena Portacolone,Bernadette Siddiqi,Nina Silverberg,Rueben C. Warren,Kathleen A. Welsh‐Bohmer,Rebecca M. Edelmayer,(unknown)	7
9	Identifying predictive factors of patient dropout in Alzheimer’s disease clinical trials 2021 ·Alzheimer s & Dementia ·Kimberly Crimin,Patricia Jackson Allen,(unknown),(unknown),(unknown),Hiuyan Lau,Jingshu Liu,(unknown),Nahome Fisseha,Hana Florian	2
10	P1‐050: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER'S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY 2019 ·Alzheimer s & Dementia ·Hana Florian,Steven E. Arnold,Randall J. Bateman,Joel B. Braunstein,Kumar Budur,Diana Kerwin,Holly Soares,Deli Wang,David M. Holtzman	1
11	O3‐09‐05: PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER'S DISEASE 2018 ·Alzheimer s & Dementia ·Holly Soares,Sheng Feng,Hana Florian,Michael Gold,(unknown),Nuno Mendonça,Beatrice Rendenbach‐Mueller,Kumar Budur	1
12	O1‐02‐06: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96‐WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY 2018 ·Alzheimer s & Dementia ·Hana Florian,Kumar Budur,Deli Wang,Weining Robieson,Holly Soares,Joel B. Braunstein,(unknown),Randall J. Bateman,Beatrice Rendenbach‐Mueller,Nuno Mendonça	2
13	[O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE 2017 ·Alzheimer s & Dementia ·Kumar Budur,Tim West,Joel B. Braunstein,I. Fogelman,Yvette Bordelon,Irene Litvan,Erik D. Roberson,(unknown),Philip B. Verghese,Randall J. Bateman,Hana Florian,Deli Wang,Davis C. Ryman,Laura M. Gault,Sandra Goss,Nuno Mendonça,Beatrice Rendenbach‐Mueller,Diana Kerwin,Adam L. Boxer,David M. Holtzman	9
14	Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies. 2017 ·PubMed ·Tim West,Yan Hu,Philip B. Verghese,Randall J. Bateman,Joel B. Braunstein,I. Fogelman,(unknown),Hana Florian,Nuno Mendonça,David M. Holtzman	106
15	Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study 2016 ·Journal of Alzheimer s Disease ·Hana Florian,Andreas Meier,Serge Gauthier,Stanley Lipschitz,(unknown),Qi Tang,Ahmed A. Othman,Weining Robieson,Laura M. Gault	31
16	P4‐353: A PHASE 2 TRIAL OF THE EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT‐126 AS AN ADD‐ON TREATMENT IN MILD‐TO‐MODERATE ALZHEIMER'S DEMENTIA 2014 ·Alzheimer s & Dementia ·Laura M. Gault,Andreas Meier,Hana Florian,Serge Gauthier,(unknown),Qi Tang,Ahmed A. Othman	6
17	O1‐05‐02: EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT‐126 AS A MONOTHERAPY TREATMENT IN MILD‐TO‐MODERATE ALZHEIMER'S DEMENTIA: RESULTS OF A PHASE 2B TRIAL 2014 ·Alzheimer s & Dementia ·Ahmed A. Othman,Andreas Meier,(unknown),Hana Florian,Laura M. Gault,Qi Tang	11
18	The H₃antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers 2013 ·British Journal of Clinical Pharmacology ·Ahmed A. Othman,George M. Haig,Hana Florian,Charles Locke,Lev Gertsik,Sandeep Dutta	15
19	Safety, tolerability and pharmacokinetics of the histamine H₃ receptor antagonist, ABT‐288, in healthy young adults and elderly volunteers 2012 ·British Journal of Clinical Pharmacology ·Ahmed A. Othman,George M. Haig,Hana Florian,Charles Locke,Jun Zhang,Sandeep Dutta	14
20	A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. 2008 ·PubMed ·Philip J. Mease,I. Jon Russell,Lesley M. Arnold,Hana Florian,James P. Young,Susan Martin,Uma Sharma	217

About Hana Florian

Hana Florian is a scholar working on Health Informatics, Psychiatry and Mental health and Physiology, having authored 20 papers that have together received 502 indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). The work is most often cited by research in Pharmacology (256 citations), Psychiatry and Mental health (219 citations) and Biological Psychiatry (27 citations). Hana Florian has collaborated with scholars based in United States, Germany and Egypt. Frequent co-authors include I. Jon Russell, Philip J. Mease, Susan Martin, Lesley M. Arnold, James P. Young, Uma Sharma, Ahmed A. Othman, Nuno Mendonça, Randall J. Bateman and Philip B. Verghese. Their work appears in journals such as Brain, Journal of Alzheimer s Disease and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact